Linked Life Data

12613512

Source:http://linkedlifedata.com/resource/pubmed/id/12613512

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2003-3-4
pubmed:abstractText
Human blood cells, except for erythrocytes and platelets, express CD81, a member of the transmembrane 4 superfamily (TM4SF). CD81 is also expressed on most of human immature hematopoietic cells, CD34+ cells, which are divided into three populations according to the expression of CD34 and CD81; CD34+CD81+, CD34+CD81(High) and CD34(Low)CD81+. Myeloid and lymphoid progenitors exist in the CD34+CD81+ population, and megakaryocytic progenitors are only in CD34(Low)CD81+ population. Erythroid and multipotential progenitors are shared by CD34+CD81+ and CD34(Low)CD81+ populations, but multipotential progenitors in the CD34+CD81+ population have already lost most of their myeloid potential. NK cells and mast cells can be generated from all three populations. Long-term repopulating (LTR) lymphohematopoietic stem cells are present in the CD34+CD81+ population. Based on these findings, we propose a model for the development of CD34+CD81+ lymphohematopoietic stem cells. Along the differentiation cascade from CD34+CD81+ lymphohematopoietic stem cells, there appear to be pathways to CD34(Low)CD81 + or CD34+CD81(High) cells, even if they are indirect. CD34(Low)CD81+ pathways define the loss of LTR ability, and lymphoid and myeloid potentials, whereas CD34+CD81(High) pathways represent the exclusive commitment to NK cells and mast cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1042-8194
pubmed:author
pubmed:issnType
Print
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2269-73
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Development of human lymphohematopoiesis defined by CD34 and CD81 expression.
pubmed:affiliation
Division of Cellular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. tsujik@ims.u-tokyo.ac.jp
pubmed:publicationType
Journal Article, Review